Wei Ding, M.B.B.S., M.D.

Closed for Enrollment

• A Phase Ib/II Study of Idelalisib in Combination with BI 836826 in Subjects with Chronic Lymphocytic Leukemia Rochester, Minn.

  The purpose of this study is to evaluate the safety and tolerability of the combination of idelallisib with the monoclonal antibody BI 836826 for the treatment of patients who have chronic lymphocytic leukemia that has returned or is resistant to treatment.